Single-center experience with wearable cardioverter-defibrillator as a bridge before definitive ICD implantation

Giacomo Mugnai a,*, Antonio Lupo a, Francesca Zerbo a, Salvatore Saccà a, Franco Zoppo a, b

a Cardiac Pacing and Electrophysiology, Cardiology Department, Public Hospital of Mirano, Mirano, VE, Italy
b Electrophysiology, Cardiology Department, Public Hospital of Gorizia, Gorizia, Italy

ABSTRACT

Background: The wearable cardioverter-defibrillator (WCD) has been approved for patients with poor left ventricular ejection fraction (LVEF) who are at risk of sudden arrhythmic death for a limited period but are not candidates for a definitive implantable cardioverter-defibrillator (ICD). The present study sought to retrospectively analyse our single-centre experience.

Methods and results: All consecutive WCDs applied between April 2017 and September 2018 in our centre were enrolled. An exercise test was performed in all patients in order to evaluate the absence of false detection of ventricular arrhythmias by the device. A total of 16 patients (57.7 ± 14.8 years old; 75% males) were taken into consideration for the analysis. Mean LVEF was 32 ± 11% at diagnosis and 42 ± 10% at last follow-up (mean, 3.1 ± 1.7 months; median, 3 months). At the end of the "wearing period" 11/16 patients (69%) did not have ICD implant indications and only 5 (31%) underwent ICD implantation. Neither appropriate nor appropriate shocks occurred during the follow up.

Conclusions: The WCD represents a useful tool to bridge a temporarily increased risk for sudden cardiac death. The proportion of patients with an improvement of LVEF > 35% beyond the WCD-application period was considerable.

1. Introduction

Nowadays, the implantable cardioverter-defibrillator (ICD) is the gold standard for the prevention of sudden cardiac death due to ventricular tachyarrhythmias [1,2]. Current guidelines recommend ICD implantation for secondary and primary prevention in patients with an established high risk of sudden cardiac death (SCD) [3,4]. However, in selected patients, the risk of SCD may be increased only temporarily or cannot be immediately determined. The wearable cardioverter-defibrillator (WCD) has been approved for clinical practice in 2001 to bridge a period of presumed high risk of SCD [5,6]. The 2015 guidelines of the European Society of Cardiology give a IIb, level of evidence C indication for WCD in case of patients with poor left ventricular systolic function who are at risk of sudden arrhythmic death for a limited period but are not candidates for an ICD (i.e. bridge to transplant, bridge to transvenous implant, peripartum cardiomyopathy, active myocarditis, and arrhythmias in the early post-myocardial infarction phase) [4]. The present study sought to retrospectively analyse our single-centre experience with a relatively small sample of patients treated with WCD.

2. Methods

The current study is a retrospective analysis based on all consecutive WCDs applied between April 2017 and September 2018 in our centre to those patients at risk of sudden arrhythmic death for a limited period and without an immediate indication to ICD implantation.

All patients were fitted with the device, trained in its use, and instructed to wear the device continuously for 3 months (except while bathing). According to the PROLONG study [7], those patients who presented an increase in left ventricular ejection fraction (LVEF) ≥5% or from 30% to 35% received a prolongation of WCD application. Sites were alerted if a participant wore the device for
less than 15 h in a 24-h period (monitored through the device itself).

The database collection includes demographic information, customer call reports and device data, such as reason, compliance and duration of WCD use. Incidences of shock therapy and asystole (defined as ECG signal amplitude below 100 µV for at least 16 s) were reviewed from ECG recordings. Sudden cardiac arrest included both sustained (lasting 30 s) ventricular tachycardia (VT) or ventricular fibrillation (VF), as detected through programmed rate criteria. An exercise test was performed in all patients in order to evaluate the absence of false detection of ventricular arrhythmias by the device.

Compliance with device use for each patient was calculated by averaging the hours used per day of wear. The time to deliver therapy was programmed as follows: 60 s for VT and 25 s for VF. The VT and VF zones were programmed, respectively, >150 bpm and >200 bpm in all patients except one, who received a more conservative programation (VT and VF zone respectively >170 and >220 bpm).

A detailed description of the WCD (LifeVest® device, ZOLL, Pittsburgh, PA, USA) has been provided in prior publications and reviews [7,8]. In case of sensed ventricular arrhythmic episodes, the WCD is able to deliver a treatment shock through three self-gelling defibrillation electrodes. The WCD stores data on device usage and all ECGs associated with arrhythmia detection, which are then uploaded to the company server to be reviewed and evaluated by the treating physician.

Categorical variables are expressed as absolute and relative frequencies. Continuous variables are expressed as mean ± SD or median and range as appropriate. Statistical analysis was performed using SPSS 20.0.0 (IBM Inc., Armonk, New York, USA).

3. Results

A total of 16 patients (57.7 ± 14.8 years old; 75% males) were enrolled in the study. The characteristics of the study population are listed in Tables 1 and 2. As Fig. 1 shows, the underlying reasons for WCD application were: dilated cardiomyopathy with impairment of LVEF following myocardial infarction (n = 4; 25%), myocarditis (n = 4; 25%), chemotherapy (n = 2; 12%), alcohol abuse (n = 1; 6%), and related to unknown causes in 3 patients (19%); in addition, 2 patients (12%) were recruited because of ventricular arrhythmias under diagnostic definition. The patients wore the device for a mean time of 3.1 ± 1.7 months (median: 3 months) and for a mean daily time of 22.3 ± 1.9 h (median 23.3 h). The mean wear time was 91.2 ± 44.1 days.

No patients presented sustained ventricular arrhythmias during the observation period; neither appropriate nor inappropriate shocks were delivered by the device. Of note, in 3 patients (19%) the WCD reported episodes of high ventricular rates which the medical review actually labelled as sinus tachycardias. Two patients (12%) had already a story of persistent atrial fibrillation and another one (6%) had a paroxysmal episode of atrial fibrillation during the hospital stay. Of note, 11 patients (69%) exhibited non sustained ventricular tachycardias before WCD application.

Mean LVEF was 32 ± 11% at diagnosis and 42 ± 10% at last follow-up (mean, 3.1 ± 1.7 months; median, 3 months). At last follow up and after the clinical re-evaluation, 11 patients (69%) did not have indication for a definitive ICD. Five patients (31%) underwent ICD implantation, of them received a single-chamber device, another one received a biventricular device and the fourth one a subcutaneous ICD. Finally, one patient (6%) showed a marked reduction in ventricular arrhythmias under therapy with amiodarone and a loop recorder implantation was decided to monitor the patient during the follow up.

4. Discussion

Although the present cohort study is limited by the relatively low number of patients and, subsequently, the absence of malignant arrhythmic events, the following observations can be drawn: (1) no inappropriate shocks released by the device occurred; (2) the mean wear time per day was high; (3) the rate of patients who did not present indications for ICD at last follow up was high, especially for those patients who received a prolonged WCD application period.

Some studies reported the occurrence of inappropriate shock delivered by WCD. Olgin et al. [9] reported a rate of 0.6% of inappropriate shock (9/1524) in a recente, large, randomized and prospective study investigating the usefulness of WCD in the early phase after acute myocardial infarction. In the PROLONG study [7], Duncker et al. did not report any inappropriate shocks in 156 patients with newly diagnosed LVEF < 35%. Our patient population did not experience any inappropriate shock but this finding is limited by the very small number of patients. However, in our protocol an exercise test was systematically performed in all patients in order to evaluate the absence of false detection of ventricular arrhythmias by the device. This might have hypothetically been useful to avoid inappropriate shocks during the follow-up period.

In our study the mean wear time per day was high when compared with the literature; for instance, the PROLONG study [7] and Olgin et al. [9] reported a mean wear time per day of 21.7 ± 4 and 14.0 ± 9, respectively. The latter did not find a significant lower rate of arrhythmic death or total mortality in patients with WCD compared with those without WCD. However, the authors interestingly reported in the as-treated analysis that patients who chose to wore the device, having a better compliance and higher mean wear time per day, presented a significant reduction both in arrhythmic death and in total mortality (respectively, p = 0.03 and p < 0.001). Therefore, the compliance and the mean wear time might probably be crucial for the decrease of arrhythmic and overall mortality. In our study the compliance and mean wear time per day were satisfactory; however, as no arrhythmic events occurred in our patient population, any inference about these aspects and malignant arrhythmic episode and mortality could not be done.

The rate of patients who did not implant ICD at the end of the WCD period was high (69%); these data are in line with the findings of the PROLONG study [7], which reported that 63% of initial patients with LVEF <35% experienced a significant improvement in the left ventricular systolic function and avoided a permanent ICD.

Table 1
Clinical characteristics and medical therapy of the study population.

| Clinical features | Value |
|-------------------|-------|
| Age (years)       | 57.7 ± 14.8 |
| Male gender       | 12 (75%) |
| Hypertension      | 5 (31%) |
| Dyslipidemia      | 4 (25%) |
| Diabetes          | 5 (31%) |
| Medical therapy   |       |
| ACE inhibitors/sartans | 10 (62%) |
| Beta blockers     | 14 (87%) |
| Amiodarone        | 6 (37%) |
| Sacubitril/valsartan | 2 (12%) |
| Diuretics         | 13 (81%) |
| MRAs              | 12 (75%) |
| Statins           | 8 (50%) |

ACE: angiotensin-converting enzyme; MRA: mineralocorticoid receptor antagonist.
implantation. Of note, the prolongation of WCD period >3 months because of initial increase of LVEF resulted in a higher proportion of patients with a recovery of LVEF >35%. In the present study, 4 patients received WCD for >3 months because of a partial increase of LVEF; as shown in Tables 1 and 3 of them (75%) presented an improvement of LVEF over 35% and indications for ICD implantations faded out in these patients. Finally, the WCD might also be an helpful tool for the detection of supraventricular arrhythmias during the follow up of these patients.

It should be specified that although the current practice accepts a LVEF cut off of 35% is based on MADIT II [10] and SCDHeFT [11] trials, the arrhythmic risk is not binary but it is present through the entire continuum of LVEF with a reverse trend, the more the LVEF increases the more arrhythmic risk decreases but it never abolishes [12].

The relative small number of patients and heterogeneity of the

| Patient | Age | Gender | Indications | WCD application time (months) | Daily average of use (hours) | Medical therapy | LVEF before (%) | LVEF after (%) | Outcome |
|---------|-----|--------|-------------|-------------------------------|-----------------------------|----------------|----------------|--------------|---------|
| #1      | 73  | male   | Ischemic DCM | 3                             | 23.9                        | ACEi, BB, D, AA, statin | 35             | 35           | ICD implantation |
| #2      | 57  | male   | Post-myocarditis DCM | 4                             | 22.7                        | ACEi, BB, D, AA, statin | 30             | 30           | no ICD               |
| #3      | 57  | male   | Idiopathic DCM | 2                             | 23.6                        | BB, amio, D, AA, statin  | 54             | 54           | no ICD               |
| #4      | 56  | female | Post-chemotherapy DCM | 5                             | 19.1                        | ACEi, BB, amio, D, AA | 29             | 29           | no ICD               |
| #5      | 56  | female | Ventricular arrhythmias | 2                             | 23.8                        | ACEi, BB, D, AA, statin | 34             | 34           | ICD implantation    |
| #6      | 14  | male   | Ventricular arrhythmias | 2                             | 23.1                        | ACEi, BB, D, AA        | 25             | 25           | CRT implantation    |
| #7      | 57  | male   | Ischemic DCM | 3                             | 23.9                        | ACEi, BB, amio, D, AA, statin | 30             | 30           | no ICD               |
| #8      | 56  | female | Post-chemotherapy DCM | 2                             | 22.2                        | BB, amio              | 58             | 58           | no ICD               |
| #9      | 59  | male   | Post-myocarditis DCM | 3                             | 20.6                        | ACEi, BB, D, AA, statin | 30             | 30           | no ICD               |
| #10     | 45  | male   | Ischemic DCM | 4                             | 23.5                        | BB, D, AA             | 30             | 30           | no ICD               |
| #11     | 63  | male   | Idiopathic DCM | 3                             | 23.7                        | BB, S/V, D, AA        | 30             | 30           | no ICD               |
| #12     | 53  | female | Post-chemotherapy DCM | 4                             | 18.2                        | ACEi, BB, AA, D, AA, statin | 23             | 23           | no ICD               |

WCD: wearable cardioverter-defibrillator, LVEF: left ventricular ejection fraction, DCM: dilated cardiomyopathy, ACEi: angiotensin converting enzyme inhibitors, BB: beta blockers, D: diuretics, AA: anti-aldosteronics, ICD: implantable cardioverter-defibrillator, S/V: sacubitril/valsartan, amio: amiodaron, CRT: cardiac resynchronization therapy.
underlying aetiologies represent important limitations. Moreover, another limitation is that patients did not receive a further arrhythmic risk stratification beyond the LVEF assessment.

In conclusion, the WCD may represent a useful tool for patients with poor LVEF who are at risk of sudden arrhythmic death for a limited period but are not candidates for a definitive ICD. The present study reports an optimal profile of compliance after adequate training of the patient; neither arrhythmic death nor inappropriate shock occurred. The proportion of patients with an improvement of LVEF > 35% beyond the WCD period was considerable as already shown by previous studies. However, as the present study includes a small population and no arrhythmic events occurred during the follow period, no conclusions about arrhythmic detection and treatment of this device can be drawn. Larger, randomized, controlled studies are needed to confirm the effectiveness of this technology and to identify the subgroup of patients who might benefit from this technology.

Declaration of competing interest

The authors report no relationships that could be construed as a conflict of interest.

Acknowledgements

We would like to thanks Salvatore Butera and Alberto Favaro, employees of ZOLL for the precious collaboration in the collection of data and technical informations about the device.

References

[1] Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, Boczor S, Domanski M, Follmann D, Gent M, Roberts RS. Meta-analysis of the implantable cardioverter-defibrillator secondary prevention trials. Eur Heart J 2000;21:2071–8.
[2] Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–37.
[3] Epstein AE, DiMarco JP, Ellenbogen KA, Estes 3rd NA, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith Jr SC, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Etttinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. J Am Coll Cardiol 2008;51:e1–62.
[4] Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggreve M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolau N, Norekvål TM, Spaulding C, Van Veldhuisen DJ. ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of Cardiology (ESC). Endorsed by: association for European paediatric and congenital Cardiology (AEP). Europace 2015;17:1801–87. 2015.
[5] Aurichio A, Klein H, Geller CJ, Reek S, Heilman MS, Szymbikiewicz SJ. Clinical efficacy of the wearable cardioverter-defibrillator in acute terminating episodes of ventricular fibrillation. Am J Cardiol 1998;81:1253–6.
[6] Feldman AM, Klein H, Tchou P, Murali S, Hall WJ, Mancini D, Boehmer J, Harvey M, Heilman MS, Szymbikiewicz SJ, Moss AJ. Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BROAD. Pacing Clin Electrophysiol 2004;27:4–9.
[7] Duncker D, Koning T, Hohmann S, Bauersachs J, Weltmann C. Avoiding untimely implantable cardioverter-defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter-defibrillator – the PROLONG study. J Am Heart Assoc 2017;6:1–8.
[8] Reek S, Burri H, Roberts PR, Perings C, Epstein AE, Klein HU. The wearable cardioverter-defibrillator: current technology and evolving indications. Europace 2017;19:335–45.
[9] Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, Zweibel S, Buxton AE, Elayi CS, Chung EH, Rashba E, Borigtre M, Hue TF, Maguire C, Lin F, Simon JA, Hulley S, Lee BK. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med 2018;379:1205–15.
[10] Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. Multicenter Automatic Defibrillator Implantation Trial – II (MADIT II). N Engl J Med 2002;346(12):877–83.
[11] Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Sudden cardiac death in heart failure trial (SCD-HeFT) investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–37.
[12] Gatzoulis KA, Tsiacharis D, Arsenios P, Antoniou CK, Dilaveris P, Sideris S, Kanoupos E, Vassilakou J, Frangakis V, Trachanas K, Varnardos M, Konstantinou I, Tsimos K, Xenogiannis I, Vlachos K, Saploularas A, Triantafyllou K, Kalikazaros I, Tousoulis D. Arrhythmic risk stratification in post myocardial infarction patients with preserved ejection fraction: the PREserve EF study. Eur Heart J 2019;40:2940–9.